Cullinan Therapeutics, Inc.
CGEM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $349,959 | $444,383 | $445,911 | $713,504 |
| - Cash | $103,335 | $72,820 | $76,655 | $83,005 |
| + Debt | $1,188 | $1,519 | $1,840 | $2,151 |
| Enterprise Value | $247,812 | $373,082 | $371,096 | $632,650 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$50,531 | -$75,721 | -$54,920 | -$54,971 |
| % Margin | – | – | – | – |
| Net Income | -$50,610 | -$70,055 | -$48,501 | -$47,647 |
| % Margin | – | – | – | – |
| EPS Diluted | 0 | -1.19 | -0.82 | -0.81 |
| % Growth | 100% | -45.1% | -1.2% | – |
| Operating Cash Flow | -$36,877 | -$57,609 | -$43,155 | -$36,626 |
| Capital Expenditures | $36,877 | $0 | $0 | $0 |
| Free Cash Flow | $0 | -$57,609 | -$43,155 | -$36,626 |